{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:28:27Z","timestamp":1765268907718,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s11523-023-00972-8","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T09:02:01Z","timestamp":1686128521000},"page":"593-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5204-269X","authenticated-orcid":false,"given":"Jonathan","family":"Heseltine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Allison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellati","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu-Chuen","family":"Oong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Charnley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omi","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shien","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"issue":"14","key":"972_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et\u00a0al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1712126.","journal-title":"N Engl J Med"},{"issue":"14","key":"972_CR2","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, et\u00a0al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289\u2013300. https:\/\/doi.org\/10.1056\/NEJMoa2035716.","journal-title":"N Engl J Med"},{"issue":"12","key":"972_CR3","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, et\u00a0al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1816714.","journal-title":"N Engl J Med"},{"issue":"9","key":"972_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, et\u00a0al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2026982.","journal-title":"N Engl J Med"},{"issue":"12","key":"972_CR5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, et\u00a0al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1816047.","journal-title":"N Engl J Med"},{"key":"972_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107673","volume":"98","author":"M Stellato","year":"2021","unstructured":"Stellato M, Santini D. ImmuneOncology-tyrosine kinase inhibitors combination, sometimes less is more. Int Immunopharmacol. 2021;98: 107673. https:\/\/doi.org\/10.1016\/j.intimp.2021.107673.","journal-title":"Int Immunopharmacol"},{"key":"972_CR7","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 9911830, Tivozanib. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Tivozanib"},{"issue":"30","key":"972_CR8","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","volume":"31","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Nosov D, Eisen T, et\u00a0al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31(30):3791\u20139. https:\/\/doi.org\/10.1200\/JCO.2012.47.4940.","journal-title":"J Clin Oncol"},{"key":"972_CR9","unstructured":"MedPageToday.com. FDA rejects renal cancer drug Tivozanib, 2013. Available from: https:\/\/www.medpagetoday.com\/hematologyoncology\/renalcellcarcinoma\/39736"},{"key":"972_CR10","unstructured":"National Institute for Health and Care Excellence (NICE). Single Technology Appraisal, Tivozanib for Treating Renal Cell Carcinoma [ID591], Committee Papers. 2017."},{"key":"972_CR11","unstructured":"European Medicines Agency. Summary of Opinion, Fotivda, EMA\/CHMP\/333095\/2017. Vol 2019."},{"issue":"3","key":"972_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","volume":"16","author":"JJ Ko","year":"2015","unstructured":"Ko JJ, Xie W, Kroeger N, et\u00a0al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015;16(3):293\u2013300. https:\/\/doi.org\/10.1016\/S1470-2045(14)71222-7.","journal-title":"Lancet Oncol"},{"issue":"19","key":"972_CR13","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, et\u00a0al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1510665.","journal-title":"N Engl J Med"},{"issue":"5","key":"972_CR14","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"Escudier B, Porta C, Schmidinger M, et\u00a0al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706\u201320. https:\/\/doi.org\/10.1093\/annonc\/mdz056.","journal-title":"Ann Oncol"},{"issue":"4","key":"972_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3233\/KCA-190073","volume":"3","author":"M Staehler","year":"2019","unstructured":"Staehler M, Spek A, Rodler S, et\u00a0al. Real-world results from one year of therapy with tivozanib. Kidney Cancer. 2019;3(4):235\u20139. https:\/\/doi.org\/10.3233\/KCA-190073.","journal-title":"Kidney Cancer."},{"issue":"12","key":"972_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1159\/000515951","volume":"99","author":"U Basso","year":"2021","unstructured":"Basso U, Procopio G, Fornarini G, et\u00a0al. Safety and efficacy of tivozanib in first-line mRCC: a multicenter compassionate-use study (Meet-Uro 16). Oncology. 2021;99(12):747\u201355. https:\/\/doi.org\/10.1159\/000515951.","journal-title":"Oncology"},{"issue":"8","key":"972_CR17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, et\u00a0al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1303989.","journal-title":"N Engl J Med"},{"issue":"1","key":"972_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","volume":"21","author":"BI Rini","year":"2020","unstructured":"Rini BI, Pal SK, Escudier BJ, et\u00a0al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020;21(1):95\u2013104. https:\/\/doi.org\/10.1016\/S1470-2045(19)30735-1.","journal-title":"Lancet Oncol"},{"issue":"6_suppl","key":"972_CR19","doi-asserted-by":"publisher","first-page":"TPS405","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS405","volume":"40","author":"TK Choueiri","year":"2022","unstructured":"Choueiri TK, Albiges L, Hammers HJ, et\u00a0al. TiNivo-2: a phase 3 randomised, controlled, multicentre, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one was an immune checkpoint inhibitor. J Clin Oncol. 2022;40(6_suppl):TPS405.","journal-title":"J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00972-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-00972-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00972-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T10:20:16Z","timestamp":1689243616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-00972-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-00972-8","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"type":"print","value":"1776-2596"},{"type":"electronic","value":"1776-260X"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"17 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J. Heseltine has received speaker fees from EUSA. J. Allison has had conference fees paid for by EUSA. T. Waddell has received speaking fees from EUSA and IPSEN. N. Charnley has received speaking fees IPSEN. S. Chow has received speaking fees EUSA. S. Wong, K. Prasad, Z. Oong, H. Wong, A. Law and O. Parikh declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This research was conducted following approval by every local Research and Ethics Approval Committee related to each of the centres that took part.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research and Ethics Approval"}},{"value":"Patients under the remit of each individual centre consent at the outset of their care for the use of their anonymised data in any research. All of the data shared or used during the generation of this research are anonymous.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable, no code associated with this research.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"J. Heseltine (protocol\/project development, data collection or management, data analysis, manuscript writing\/editing). J. Allison (protocol\/project development, data collection or management, data analysis, manuscript writing\/editing). S. Wong (data collection or management). K. Prasad (data collection or management). Z. Oong (data collection or management). H. Wong (formal analysis). A. Law (formal analysis). N. Charnley (data collection or management, manuscript writing\/editing). O. Parikh (data collection or management). T. Waddell (protocol\/project development, manuscript writing\/editing). S. Chow (protocol\/project development, manuscript writing\/editing).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contribution"}}]}}